Respiratory Medicines · LP-073
Salbutamol Nebulizer solution
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-073Respiratory Medicines
- Generic identity
- SalbutamolNebulizer solution
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-073
- Generic identity
- Salbutamol
- Presentation
- Nebulizer solution
- Catalogue strength
- 2.5 mg/2.5 mL; 5 mg/2.5 mL
- Catalogue pack
- Unit-dose nebules; carton 20
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: salbutamol.
- Dosage form/route: nebulizer solution.
- Proposed concentrations: 2.5 mg/2.5 mL and 5 mg/2.5 mL.
- General proposed pack: unit-dose nebules; carton 20.
Layer 02 · Unresolved product-specific fields
- Exact salt/base expression and unit-container composition.
- Whether either presentation requires dilution and what diluent/compatibility instructions apply.
- Nebulizer/device compatibility, unit-after-opening and microbial/handling instructions.
- Approved indication, age range, storage, shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 2.5 mg/2.5 mL | Nebulizer solution | — | Unit-dose nebules; carton 20 | Dilution, device compatibility and in-use handling require exact product documentation. |
| B | 5 mg/2.5 mL | Nebulizer solution | — | Unit-dose nebules; carton 20 | Dilution, device compatibility and in-use handling require exact product documentation. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Salbutamol, called albuterol in the United States, is a short-acting bronchodilator that relaxes airway smooth muscle. Oral and inhaled presentations have materially different delivery characteristics and are not interchangeable by volume or stated strength. Inhaled formulations are used in respiratory treatment plans; an oral syrup should not be portrayed as an equivalent rescue inhaler. This ingredient profile does not constitute an approved Luang Pharma respiratory indication.
Clinical context and therapeutic role
Respiratory symptoms require a diagnosis and a written plan appropriate to asthma, chronic obstructive pulmonary disease or another condition. Bronchodilation can relieve narrowing of the airways, but salbutamol does not replace anti-inflammatory treatment when that is needed. Increasing reliance on a reliever or decreasing benefit can signal deterioration. Severe breathlessness, inability to speak normally, bluish coloration or exhaustion needs urgent care rather than repeated unsupervised use.
Selected safety context
Tremor, headache, palpitations and a faster heartbeat may occur. Excess exposure can cause dangerous heart rhythm problems and low potassium. Worsening wheeze immediately after inhalation may represent paradoxical bronchospasm and needs urgent review. Heart disease, thyroid disease, diabetes and interacting medicines should be considered. The prescribed device or formulation and its instructions must be followed. An oral product should never be substituted into a nebulizer or inhaler.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue uses the term nebulizer solution. The actual physical form, concentration, fill volume and compatible nebulizer system require confirmation from authorized information. Some medicines in this class are supplied as suspensions, so that distinction must be resolved. Inhalation products are not for injection or swallowing.
Use only the specified compatible nebulizer and follow cleaning and single-use instructions where applicable. Do not mix with other medicines or diluents unless compatibility is explicitly established. Storage and any period after opening an ampoule must come from the exact supplied product.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A respiratory-care professional should verify the diagnosis, inhaled-versus-oral role, exact device and technique where applicable. The patient requires a clear plan for worsening symptoms, with regular review of control and adverse effects.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product formula/specification for each concentration and unit container.
Approved inhalation-solution label/leaflet with dilution/administration directions.
Nebulizer compatibility and unit-dose handling evidence.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Albuterol sulfate inhalation solutionArchived source classification: US official drug label example | Source revision recorded: Label updated 10 December 2025; Archived access check: 2026-09-11 | Comparator official nebulizer-solution label; not Luang Pharma labelling or equivalence evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-073.
Professional enquiries
Request product-specific evidence for LP-073.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.